Investigating the ketogenic diet as treatment for primary aggressive brain cancer: challenges and lessons learned
- 1College of Human and Osteopathic Medicine, Michigan State University, United States
- 2Nutrition, Sparrow Hospital, United States
- 3Department of Pathology, Sparrow Hospital, United States
Survival of glioblastoma multiforme with the current recommended treatment is poor. Reported median survivals are approximately 8-15 months. Based on recent publications from animal models, combining cancer drugs, radiation and diet-metabolic treatments may be a new route to better survivals. To investigate this possibility, we have begun a clinical trial that has enrolled 15 subjects using a ketogenic diet as an addition to current standard treatments that include surgery, radiation therapy and chemotherapy. Of the 15 enrolled 10 completed the protocol.
This perspective describes the challenges and lessons learned during this clinical trial and discusses the critical elements that are essential for investigating treatment with a KD. We also reviewed and compared various types of KDs. We believe that the diet selected should be standardized within individual clinical trials, and more importantly, the patients’ blood should be monitored for glucose and ketones twice daily so that the supervising dietitian can work with the patient and their caregivers to make appropriate changes in the diet. Compliance with the diet is best in highly motivated patients who have excellent home support from a family member or a friend who can help to overcome administrative, physical and cognition deficiencies associated with the disease. Treatment of glioblastoma multiforme using a KD represents a reasonable investigative approach. This perspective summarizes the challenges and lessons learned implementing and continuing KD therapy while the patients are concurrently being treated with radiation and chemotherapy.
Keywords: Ketogenic Diet, Glioblastoma, Pilot Study, Lessons learned, Blood ketones
Received: 13 Nov 2017;
Accepted: 25 Jan 2018.
Edited by:Ana Preto, University of Minho, Portugal
Reviewed by:Sharon Ross, National Cancer Institute (NIH), United States
Dario Coletti, Sapienza Università di Roma, Italy
Copyright: © 2018 Schwartz, Noel, Nikolai and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: MD. Kenneth A. Schwartz, Michigan State University, College of Human and Osteopathic Medicine, 909 West Fee Rd. Rm B-309d, Michigan State University,, East Lansing, 48824, Michigan, United States, email@example.com